Literature DB >> 3169751

Are serological tests of value in diagnosing and monitoring response to treatment of syphilis in patients infected with human immunodeficiency virus?

P M Terry1, M L Page, D Goldmeier.   

Abstract

To assess the value of serological tests in diagnosing and monitoring the response to treatment of syphilis in patients infected with the human immunodeficiency virus (HIV), case notes of eight homosexual men with a history of treated syphilis, positive reactions to serological tests for syphilis, and documented subsequent conversion to HIV seropositivity were studied. No change was noted in serological markers of syphilis after HIV infection. The case notes of one man with primary syphilis, four men with secondary syphilis, and three men with latent syphilis, of whom all were HIV seropositive, were also studied. In seven of these patients the serological responses to infection and after treatment were consistent with the experience of syphilis in HIV seronegative patients. In one man treated for secondary syphilis, and confirmed as HIV seropositive eight months after treatment, the rapid plasma reagin (RPR) test result continued to be positive at a high titre for up to 20 months after treatment.

Entities:  

Mesh:

Year:  1988        PMID: 3169751      PMCID: PMC1194219          DOI: 10.1136/sti.64.4.219

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  10 in total

1.  Longitudinal immunological studies on a cohort of initially symptom-free homosexual men in London with respect to HTLV-III serology.

Authors:  A J Pinching; J N Weber; L A Rogers; E L Berrie; D J Jeffries; J R Harris
Journal:  Adv Exp Med Biol       Date:  1985       Impact factor: 2.622

2.  Syphilis in the AIDS era.

Authors:  E C Tramont
Journal:  N Engl J Med       Date:  1987-06-18       Impact factor: 91.245

3.  Failure of recommended treatment for secondary syphilis.

Authors:  D M Markovitz; K R Beutner; R P Maggio; R C Reichman
Journal:  JAMA       Date:  1986-04-04       Impact factor: 56.272

4.  Outbreak of central-nervous-system toxoplasmosis in western Europe and North America.

Authors:  B J Luft; F Conley; J S Remington; M Laverdiere; K F Wagner; J F Levine; P C Craven; D A Strandberg; T M File; N Rice; F Meunier-Carpentier
Journal:  Lancet       Date:  1983-04-09       Impact factor: 79.321

5.  Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS.

Authors:  J Dylewski; S Chou; T C Merigan
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

6.  Treatment of primary and secondary syphilis. Serological response.

Authors:  N J Fiumara
Journal:  JAMA       Date:  1980-06-27       Impact factor: 56.272

7.  Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae.

Authors:  H C Wallenburg; G A Dekker; J W Makovitz; P Rotmans
Journal:  Lancet       Date:  1986-01-04       Impact factor: 79.321

8.  Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma.

Authors:  C B Hicks; P M Benson; G P Lupton; E C Tramont
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Serological response to syphilis treatment. A new analysis of old data.

Authors:  S T Brown; A Zaidi; S A Larsen; G H Reynolds
Journal:  JAMA       Date:  1985-03-01       Impact factor: 56.272

  10 in total
  2 in total

1.  Diagnosis of neurosyphilis: appraisal of clinical caseload.

Authors:  C A Rodgers; S Murphy
Journal:  Genitourin Med       Date:  1997-12

2.  Primary and secondary syphilis, 20 years' experience. 3: Diagnosis, treatment, and follow up.

Authors:  J Anderson; A Mindel; S J Tovey; P Williams
Journal:  Genitourin Med       Date:  1989-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.